ASK1 is associated with development of fibrosis in various tissues and is a therapeutic target for fibrotic diseases, including pulmonary arterial hypertension, chronic kidney disease, and nonalcoholic steatohepatitis. Here, MAP3K5 is linked to chronic kidney disease.